IGC Pharma, Inc.

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.

メドレックス4586 · PharmaceuticalsHigashikagawa, Japan

64% matchPublic

Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption systems. Their innovation centers on technologies such as the Ionic Liquid Transdermal System (ILTS) and the Nano-sized Colloid Transdermal System (NCTS). MedRx also actively researches the pain-free transdermal delivery of various substances, including vaccines, nucleic acid medicines, and protein medicines. Its diverse product pipeline includes MRX-4TZT, undergoing Phase I clinical trials for spastic paralysis, and MRX-9FLT, also in Phase I, designed to alleviate chronic, cancer-related, and severe pain. Additionally, MRX-7MLL for Alzheimer's disease and MRX-6LDT for chronic pain are both in pre-clinical development. A notable achievement is MRX-5LBT, which has successfully concluded clinical trials for treating postherpetic nerve pain.

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

Supernus Pharmaceuticals, Inc.0LB2 · PharmaceuticalsRockville, United States

64% matchPublic

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research, development, and market introduction of therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed medications addresses a range of CNS conditions. These include Trokendi XR, an extended-release formulation of topiramate used for managing epilepsy and preventing migraine headaches, and Oxtellar XR, an extended-release oxcarbazepine prescribed as a standalone treatment for partial-onset epileptic seizures in individuals aged 6 to 17 and adults. Another key offering is Qelbree, a selective norepinephrine reuptake inhibitor specifically designed for pediatric patients (ages 6 to 17) suffering from attention-deficit hyperactivity disorder (ADHD). For Parkinson's Disease (PD), Supernus provides APOKYN for acute intermittent treatment of 'off' episodes or hypomobility in advanced stages, XADAGO to aid patients on levodopa/carbidopa experiencing 'off' periods, and GOCOVRI to treat dyskinesia. Osmolex ER is also available for PD and drug-induced extrapyramidal reactions in adults. Furthermore, the company commercializes MYOBLOC, a Type B toxin, for treating cervical dystonia and sialorrhea in adult patients. Beyond its commercialized therapies, Supernus maintains an active pipeline of investigational treatments. This includes Qelbree (SPN-812), having finished Phase III trials for ADHD, and SPN-830, a late-stage drug/device combination aiming to prevent 'off' episodes in Parkinson's patients. Also in development are SPN-817, a novel compound undergoing Phase I clinical trials for severe epilepsy, and SPN-820, currently in Phase II for refractory depression. Additionally, two preclinical-stage candidates, SPN-443 and SPN-446, are being explored for other CNS indications. The distribution of these products occurs via pharmaceutical wholesalers, specialized pharmacies, and various distributors. Established in 2005, the company maintains its principal office in Rockville, Maryland.

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.